Introduction
South Korea’s Ministry of Food and Drug Safety (MFDS) approved a total of 45 new clinical trials in December 2025, capping the year with a significant uptick in regulatory greenlights for Investigational New Drug (IND) applications. This robust monthly figure – up from 31 in November – underscores Korea’s role as a dynamic hub in the global Clinical Trials ecosystem. From cutting-edge oncology studies to next-generation vaccine trials, the clinical trials approved in December reflect a diverse pipeline driven by both domestic innovation and international collaboration. Below we break down the key statistics from the MFDS IND approval data, accompanied by visualizations, and discuss what these trends mean for Korea and the global Clinical Trials landscape.
December 2025 Clinical Trial Approval Highlights:
- Total IND approvals: 45 new clinical trials (an increase from 31 in Nov 2025)
- Domestic vs. international: 16 trials (36%) for domestically developed drugs vs. 29 trials (64%) for internationally developed drugs – reaffirming Korea’s global trial hub status
- Phase distribution: Phase 3 clinical trials led with 13 approvals, followed by Phase 1 (10) and Phase 2 (9); multiple adaptive or combined-phase clinical trials (Phase 1/2, 2/3, etc.) were also notable
- Top therapeutic area: Oncology dominated with 21 clinical trials (~47% of total), far outpacing other areas like vaccines/infectious disease (6 trials) and rare diseases (4 trials)
- Full data access: The complete December 2025 MFDS IND approval dataset is available for download on our company website for those seeking detailed trial-by-trial information.
IND Approvals by Development Origin: Domestic vs. International
Korea’s clinical trial landscape in December saw nearly two-thirds of IND approvals for drug candidates developed overseas. Out of 45 approvals, 29 trials (about 64%) were for internationally developed products, while 16 trials (36%) were for domestic developments. This domestic vs. international ratio highlights how global pharmaceutical firms continue to leverage Korea’s fast regulatory timelines and high-quality research infrastructure for their late-stage Clinical Trials, even as homegrown Korean biotech and pharma companies contribute a substantial share of new studies. The bar chart below compares the number of IND approvals for domestic and foreign-developed drug candidates in December.
Notably, the predominance of internationally sponsored clinical trials (29 approvals) underscores South Korea’s status as a preferred location for multi-national studies. Global players are increasingly conducting Phase 2 and Phase 3 clinical trials in Korea, attracted by the MFDS’s efficient review process and the country’s well-established patient recruitment and hospital networks. Meanwhile, the 16 domestic trials approved indicate a vibrant local R&D scene – Korean companies and research institutions are advancing their own drug candidates, often in earlier phases. This complementary structure (international late-phase trials vs. domestic early-phase trials) reflects how Korea’s regulatory environment and infrastructure support a full spectrum of clinical trials. In essence, overseas firms trust Korea for pivotal trials, and local firms are stepping up innovation through initial human studies.
IND Approvals by Trial Phase
When examining December’s MFDS approvals by phase, we see a balanced spread across early and late-stage clinical trials with a tilt toward Phase 3. Phase 3 trials accounted for 13 approvals, the highest of any category, indicating many programs are in confirmatory or pivotal stages. Phase 1 trials were close behind with 10 approvals, reflecting continued growth in first-in-human and dose-escalation studies (particularly among domestic sponsors). Phase 2 trials represented 9 approvals. Additionally, a significant number of INDs fell into adaptive or combined-phase categories – including 6 trials in Phase 1/2 and a few seamless-design trials like Phase 2b/3 (2 trials) and Phase 2/3 (1 trial) – as well as specialized phases like Phase 1b (2 trials) and Phase 3b (1 trial) for sub-studies and post-approval research. The chart below illustrates the distribution of approvals by trial phase.
This phase distribution reveals two key trends in Korea’s clinical trials activity. First, the abundance of Phase 3 trials (including Phase 3b and Phase 2/3 adaptive trials) largely comes from international sponsors. Global pharmaceutical companies such as Pfizer, Merck (MSD), Janssen, and others are running large late-stage clinical trials in Korea – for example, pivotal studies in oncology and immunology – underscoring the country’s strategic importance for completing enrollment in multi-center trials. Second, the strong showing of Phase 1 trials (including Phase 1b and Phase 1/2) highlights how domestic companies and research hospitals are driving early-stage clinical trials. Korean biotechs like In2Cell, Onconic Therapeutics, and academic centers like Asan Medical Center received IND approvals to test novel drug candidates (from targeted cancer therapies to stem-cell treatments) in first-in-human studies. This indicates a growing pipeline of innovative compounds originating in Korea. The coexistence of many Phase 1 and Phase 3 trials in the approval mix suggests a healthy pipeline feeding new trials at one end, and global late-phase activity at the other – positioning Korea as a cradle-to-commercialization locale for Clinical Trials.
Therapeutic Area Breakdown of Approved Trials
Oncology was once again the dominant therapeutic area for MFDS IND approvals, continuing a global trend in drug development. In December 2025, oncology trials accounted for 21 out of 45 approvals, roughly 47% of all clinical trials cleared by MFDS that month. This includes a wide array of cancer clinical trials – from solid tumor studies in lung, gastric, and colorectal cancers to hematologic malignancies like lymphoma and leukemia. The next largest category was infectious disease and vaccines, with 6 approvals (13%), driven by COVID-19 vaccine trials and other vaccine studies (e.g. a varicella vaccine study in children and a shingles vaccine trial in adults). Rare diseases and genetic disorders made up 4 approvals (9%), reflecting INDs in niche areas like Prader-Willi syndrome and focal segmental glomerulosclerosis (a rare kidney disease). Cardiovascular/metabolic trials accounted for 3 approvals (including a major outcomes trial of an oral diabetes drug in patients with heart and kidney risk). Neurology/CNS saw 2 approvals (e.g. a trial for major depressive disorder). Respiratory diseases had 2 as well (including an idiopathic pulmonary fibrosis study). Other fields, each with a single trial (2% each), included gastroenterology/immunology (Crohn’s disease), musculoskeletal (osteoarthritis), and a notable “Other” category of 5 healthy volunteer pharmacology studies without a specific therapeutic focus. The horizontal bar chart below summarizes the therapeutic area distribution of December’s IND approvals.
The prevalence of oncology clinical trials is unsurprising – it reaffirms that cancer research remains at the forefront of drug development in Korea, mirroring global R&D priorities. Within the oncology segment of the December approvals, multiple trials involve advanced modalities such as immunotherapy and targeted drugs: for instance, a bispecific antibody trial in refractory lymphoma, a personalized mRNA cancer vaccine for lung cancer, and combination studies with antibody-drug conjugates. This indicates that Korean sites are participating in some of the most cutting-edge clinical trials in oncology. The strong showing of vaccine and infectious disease trials (13% of approvals) points to ongoing efforts in pandemic-related and other vaccine development – notably, Korean firms like GC Biopharma and EuBiologics obtained IND approvals for COVID-19 vaccine candidates and SK bioscience for a pediatric varicella vaccine, highlighting Korea’s contributions to global vaccine R&D. Meanwhile, the presence of rare disease trials and other specialized areas underscores a broadening of focus: Korean regulators are supporting clinical trials in small patient-population diseases (often in collaboration with global sponsors), which could bring novel therapies for unmet medical needs. Finally, the cluster of clinical trials in healthy volunteers (categorized as “Other”) signals that a number of pharmacokinetic and formulation studies are being run in Korea – a common practice for global companies to collect data in Asian populations or to support local regulatory filings. Together, these patterns demonstrate a diversified Clinical Trials portfolio, with oncology at the helm, and significant activity in vaccines, specialty diseases, and early-phase pharmacology studies.
Domestic vs. Global: Strategic Insights and Trends
The December approval data provides strategic insight into how Korea fits into the global drug development puzzle. International sponsors dominated the late-phase trials, leveraging Korea’s patient pools for Phase 3 clinical trials in areas like oncology, immunology, and rare diseases. This trend is evidenced by companies such as Janssen and Novartis launching pivotal trials in prostate cancer and cardiovascular outcomes respectively, and Merck (MSD) running extensive cancer vaccine trials in Korean sites. The fact that overseas-developed drugs comprised 64% of approvals indicates that Korea is firmly entrenched as a go-to location for global clinical trials, especially for Phase 2b/3 and Phase 3 studies that require rapid enrollment and high-quality data. Korean investigators and hospitals are gaining further experience with cutting-edge therapies (CAR-T cells, T-cell engagers, next-gen ADCs, etc.) through these collaborations, enhancing Korea’s reputation and expertise in conducting complex Clinical Trials.
On the other hand, domestic Korean companies are actively expanding their innovation footprint, as seen in the 16 locally developed drug IND approvals. The majority of these were early-phase clinical trials (with 7 of the 16 being Phase 1 studies), reflecting a strategic focus on initial safety and dosing studies for novel Korean compounds. Standout examples include a Korean biotech advancing a first-in-class oncology molecule into humans and a local hospital-led trial of a stem-cell therapy for spinal cord injury – the latter showcasing academia’s role in Korean clinical trials. Korean vaccine developers also featured prominently among domestic approvals, pointing to strong local capabilities in vaccine R&D (e.g. a Cha Vaccine Institute trial for a new shingles vaccine). The trend suggests that while global pharmas utilize Korea for later stages, Korean firms are building pipelines from the ground up, which in time could progress to larger trials and international partnerships.
Another notable insight is the regulatory efficiency and capacity of the MFDS, which managed 45 IND approvals in a single month. This pace indicates that Korea’s regulatory framework can accommodate high volumes of clinical trial applications, a reassuring sign for sponsors planning multi-study programs. It aligns with recent MFDS initiatives to streamline approvals and support simultaneous global development
For industry professionals, these trends mean that engaging with Korea’s clinical trial environment can offer accelerated timelines and access to a vibrant research ecosystem. Moreover, the data hints at emerging areas to watch: for instance, the presence of metabolic disease outcomes trials (such as a GLP-1 agonist study for cardiovascular prevention) suggests Korea is involved in the global race for chronic disease therapeutics, not just niche or acute conditions.
Conclusion
December 2025’s MFDS IND approvals data paints a picture of a thriving Clinical Trials hub at the crossroads of domestic innovation and international collaboration. The surge to 45 approvals in one month, heavy global participation in late-phase clinical trials, and a broad therapeutic reach (led by oncology and bolstered by vaccines and rare diseases) all highlight South Korea’s strategic importance in drug development. For pharmaceutical and biotech professionals – in Korea and around the world – these numbers and trends offer both encouragement and guidance. Korea’s clinical research infrastructure is handling cutting-edge trials across phases, making it an attractive venue for future studies. At the same time, the growth in local early-phase trials signals rising competition and opportunity in the Korean biotech sector. In summary, Korea closes out 2025 not only with a strong performance in clinical trial approvals, but with clear momentum carrying into 2026, promising an even more dynamic landscape for global Clinical Trials in the years ahead.
